gdc-0919
Small moleculeexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2014 (NCT02048709)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Indoleamine 2,3-dioxygenaseINHIBITOR
IDO1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O[C@H](C[C@H]1c2c(F)cccc2-c2cncn21)[C@H]1CC[C@H](O)CC1- Mol. weight
- 316.38 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3989951 ↗
Also known as
- gdc-0919
- gdc-0919
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05469490 | Phase 1 | Oct 31, 2022 | Lumos Pharma, University of Pittsburgh |
| NCT02471846 | Phase 1 | Jul 28, 2015 | Genentech, Roche |
| NCT02048709 | Phase 1 | Apr 1, 2014 | Genentech, Roche |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Genentech | For profit | 2 | 2 | 1 | 2014 |
| Roche | For profit | 2 | 0 | 1 | 2014 |
| Lumos Pharma | For profit | 1 | 0 | 1 | 2022 |
| University of Pittsburgh | Academic/Hospital | 1 | 1 | 1 | 2022 |
4 organizations
Page 1 / 1